Table I.
Clinicopathological characteristics of lipomatous angiomyofibroblastoma.
| Authors, year | Age (years)/gender | Location | Tumor size (cm) | % Fat cells | Immunohistochemical characteristics | Follow-up | (Refs.) |
|---|---|---|---|---|---|---|---|
| Nielsen et al, 1996 | NAa/F | NAa | NAa | NA (numerous) | NAa | NA | (5) |
| Laskin et al, 1997 | 39/F | Labium majus | 5.5 | >50 | NA | NED/6 years | (6) |
| 42/F | Labium majus | 5 | >50 | CD34+ (weak) | NED/6 years | ||
| Magro et al, 2014 | 58/F | Vulva | 3.2 | 40 | Vim+, desmin-, SMA+, CD34-, ER+, PgR+, Bcl-2+, CD99+ | NA | (7) |
| Hiruki et al, 1993 | 39/F | Vulva | 11 | NA (prominent) | Vim+, desmin+, MSA−, S-100−, factor VIII− | NA | (8) |
| Shintaku et al, 2002 | 45/M | Inguinal region | 3.9 | 30 | Vim+, desmin−, SMA−, S-100−, CD34+, ER+, PgR-, CD68-, GFAP-, CK-, EMA- | NA | (9) |
| Cao et al, 2005 | 50/F | Vulva | 1.8 | 70–80 | Vim+, desmin−, MSA−, S-100+ (rare), CD34+, ER+, PgR+, CK−, EMA−, Bcl-2+, CD10−, C-kit− | NA | (10) |
| 23/F | Labium | 7.7 | 30–40 | Vim+, desmin+, MSA+, S-100−, CD34−, ER+, PgR+, CK−, EMA−, Bcl-2+, CD10+, C-kit− | NA | ||
| Lee et al, 2010 | 46/F | Vulva | 4 | NA (several) | Vim+, desmin−, ER+, PgR+ | NED/7 months | (11) |
| Vora et al, 2011 | 41/F | Labium majus | 2.9 | 60 | Vim+, desmin-, SMA-, ER+, PgR+ | NED/6 months | (12) |
| Magro et al, 2014 | 56/F | Vulva | 4.5 | 60 | Vim+, desmin+, SMA−, S-100−, CD34−, CK−, EMA−, Bcl-2+, CD10−, C-kit−, HMB45−, CD99+ | NED/2 years | (13) |
| 69/F | Vagina | 7.5 | 60 | Vim+, desmin+, SMA−, CD34+, ER+, PgR+, Bcl-2+, CD99− | NA | ||
| Upreti et al, 2015 | 49/F | Labium majus | 6 | 60 | Vim+, desmin−, SMA−, S-100−, CD34−, ER+, PgR+, CD31−, HMB45− | NED/19 months | (14) |
| Luis et al, 2015 | 57/F | Vulva | 12 | >90 | S-100−, ER+, Βcl-2+; desmin/SMA/CD34, see commentsb | NA | (15) |
| 35/F | Labium | 6 | >90 | S-100−, ER+, Βcl-2+; desmin/SMA/CD34, see commentsb | NA | ||
| 47/F | Labium | 2.5 | 50 | S-100−, ER+, Βcl-2+; desmin/SMA/CD34, see commentsb | NA | ||
| Present case | 49/F | Vulva | 5.3 | 85 | Vim+, desmin−, SMA−, S-100−, CD34−, ER+, PgR+, CK−, EMA−, Bcl-2+, CD10+, HMB45−, p40− | NED/1 month |
a
The lipomatous component was not clearly indicated in this report.
b
Positivity for desmin, SMA and CD34 was found in 2 of 3 cases, 0 of 2 cases, and 1 of 3 cases, respectively, but these positive or examined cases were clearly described in this report. F, female; M, male; Vim, vimentin; CK, cytokeratin; EMA, epithelial membrane antigen; ER, estrogen receptor; GFAP, glial fibrillary acid protein; MSA, muscle-specific actin; NA, information not available; NED, no evidence of disease; PgR, progesterone receptor; Bcl-2, B-cell lymphoma 2; SMA, smooth muscle actin; HMB45, human melanoma black 45.